Key result
Circulating TNFalpha levels in the top third were not independently associated with incident myocardial infarction (adjusted OR 1.33; 95% CI 0.91-1.66) or stroke compared to the bottom third.
Why the study?
Do elevated circulating TNFalpha levels independently predict the risk of MI or stroke in older adults?
Case-Control (n=1,983)
Yes
Do elevated circulating TNFalpha levels independently predict the risk of MI or stroke in older adults?
Odds Ratio: 1.33 (95% CI 0.91–1.66)
Circulating TNFalpha is not a strong independent risk marker for MI or stroke when accounting for established risk factors and other inflammatory markers.
TNFα levels do not support independent risk prediction for MI or stroke; leaves open its incremental value beyond established markers in older adults.
BACKGROUND: Tumour necrosis factor alpha (TNFalpha) is a pro-inflammatory cytokine implicated in atherosclerotic plaque formation. We investigated whether circulating TNFalpha is prospectively associated with myocardial infarction (MI) or stroke in the older general population, independently of established cardiovascular risk factors and other inflammatory markers related to CHD risk. METHODS: We measured baseline TNFalpha concentrations in stored serum samples of 362 incident MI and 299 incident stroke cases and controls (2 per case, frequency matched by age, gender and town) who were 'nested' in parallel prospective studies of 4252 men and 4286 women aged 60-79 years assessed in general practices in 24 British towns in 1998-2000 and followed up for an average 7 years for fatal and non-fatal MI and stroke. RESULTS: TNFalpha levels were 11.4% (95% CI 9.5, 13.3%) higher among MI cases than controls; geometric mean 1.84 pg/mL compared to 1.63 pg/mL, p (difference)<0.001. Participants in the top third of baseline TNFalpha levels had an age-adjusted odds ratio (OR) for MI of 1.75 (95%CI 1.22, 2.49) compared with those in the bottom third, which was reduced to 1.47 (95%CI 1.01, 2.14) after adjustment for established cardiovascular risk factors. However, further adjustment for C-reactive protein and interleukin-6 abolished the association OR 1.33 (95% CI 0.91, 1.66) and the linear trend. Excluding subjects with pre-existing CVD did not materially affect results. No significant association between TNFalpha and stroke was observed. CONCLUSIONS: This study suggests that TNFalpha is not a strong independent risk marker for MI, and is not associated with risk of stroke.
No takes yet. Share an insight, caveat, or question.
Jefferis et al. (2008) conducted a case-control in Myocardial infarction or stroke (n=1,983). Circulating TNFalpha levels vs. Bottom third of baseline TNFalpha levels was evaluated on Myocardial infarction (MI) (OR 1.33, 95% CI 0.91-1.66). Circulating TNFalpha levels in the top third were not independently associated with incident myocardial infarction (adjusted OR 1.33; 95% CI 0.91-1.66) or stroke compared to the bottom third.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: